Table 1 Characteristics of patients with febrile neutropenia (FN) and gastrointestinal symptoms
Variable | Combination therapyagroup (n=22) | Monotherapybgroup (n=15) | P |
|---|---|---|---|
Age, years, mean (SD) | 44.7 (14.3) | 41.2 (11.0) | 0.43 |
Female sex | 15 (68.1) | 5 (33.3) | 0.05 |
Type of Cancer | 0.18c | ||
Acute myeloid leukemia | 6 (27.3) | 7 (46.7) | |
Acute lymphoblastic leukemia | 4 (18.2) | 2 (13.3) | |
Chronic myeloid leukemia | 1 (4.5) | 2 (13.3) | |
Multiple myeloma | 6 (27.3) | 0 (0) | |
Lymphoma | 5 (22.7) | 3 (20.0) | |
Other solid tumors | 0 (0) | 1 (6.7) | |
Relapsing underlying disease | 13 (59.0) | 12 (80.0) | 0.28 |
Clinical comorbidity | 5 (22.7) | 7 (46.6) | 0.16 |
High dose chemotherapy regimens | 12 (54.5) | 9 (60.0) | 0.74 |
Nosocomial-acquired episode of FN | 19 (86.3) | 13 (86.6) | 0.97 |
ANC at the time of diagnosis of FN, median cells/mm3 (IQR) | 80 (160) | 130 (360) | 0.47 |
ANC <100 cells/mm3 at the time of diagnosis of FN | 13 (59.0) | 6 (40.0) | 0.32 |
High-risk MASCC score | 8 (36.3) | 2 (13.3) | 0.15 |
Neutropenic enterocolitis | 1 (4.5) | 1 (6.6) | 0.99 |
Pseudomembranous colitis | 1 (4.5) | 1 (6.6) | 0.99 |
Documented aerobic bacteremia | 8 (36.3) | 9 (60.0) | 0.19 |
In vitro resistance of aerobic blood isolates to initial antibiotic treatment | 1 (4.5) | 2 (13.3) | 0.55 |